Cargando…

Management of pregnancy in cystic fibrosis

With recent therapeutic advances in care, people with cystic fibrosis (CF) are living longer and healthier lives. Development of the cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapies has led to improved function of the CFTR protein resulting in improved lung function, de...

Descripción completa

Detalles Bibliográficos
Autores principales:	Montemayor, Kristina, Tullis, Elizabeth, Jain, Raksha, Taylor-Cousar, Jennifer L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Respiratory Society 2022
Materias:	Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9584571/ https://www.ncbi.nlm.nih.gov/pubmed/36337124 http://dx.doi.org/10.1183/20734735.0005-2022

Ejemplares similares

CFTR Modulators: Impact on Fertility, Pregnancy, and Lactation in Women with Cystic Fibrosis
por: Taylor-Cousar, Jennifer L.
Publicado: (2020)

Family‐building and parenting considerations for people with cystic fibrosis
por: Kazmerski, Traci M., et al.
Publicado: (2021)

Fertility, Pregnancy and Lactation Considerations for Women with CF in the CFTR Modulator Era
por: Jain, Raksha, et al.
Publicado: (2021)

Optimizing sexual and reproductive health across the lifespan in people with cystic fibrosis
por: West, Natalie E., et al.
Publicado: (2021)

The combination of tezacaftor and ivacaftor in the treatment of patients with cystic fibrosis: clinical evidence and future prospects in cystic fibrosis therapy
por: Lommatzsch, Sherstin T., et al.
Publicado: (2019)

Impact of CFTR modulator use on outcomes in people with severe cystic fibrosis lung disease
por: Shteinberg, Michal, et al.
Publicado: (2020)

Catamenial haemoptysis in females with cystic fibrosis: a case series with review of management strategies
por: Bozkanat, Kubra M., et al.
Publicado: (2021)

Potential of anti-inflammatory treatment for cystic fibrosis lung disease
por: Taylor-Cousar, Jennifer L, et al.
Publicado: (2010)

Clinical development of triple-combination CFTR modulators for cystic fibrosis patients with one or two F508del alleles
por: Taylor-Cousar, Jennifer L., et al.
Publicado: (2019)

Engaging Stakeholders in the Development of a Reproductive Goals Decision AID for Women with Cystic Fibrosis
por: Stransky, Olivia M., et al.
Publicado: (2022)

Metabolic Alkalosis in Adults with Stable Cystic Fibrosis
por: Al-Ghimlas, Fahad, et al.
Publicado: (2012)

Newborn Screening for Cystic Fibrosis in Delaware
por: Shenoy, Ambika, et al.
Publicado: (2018)

Pregnancy in Cystic Fibrosis—Past, Present, and Future
por: Gur, Michal, et al.
Publicado: (2023)

Olfactory dysfunction in people with cystic fibrosis with at least one copy of F508del
por: Beswick, Daniel M., et al.
Publicado: (2022)

Insulin Therapy to Improve BMI in Cystic Fibrosis–Related Diabetes Without Fasting Hyperglycemia: Results of the Cystic Fibrosis Related Diabetes Therapy Trial
por: Moran, Antoinette, et al.
Publicado: (2009)

Changes in Care during the COVID-19 Pandemic for People with Cystic Fibrosis
por: Sanders, Don B., et al.
Publicado: (2022)

Genomic epidemiology of Mycobacterium abscessus in a Canadian cystic fibrosis centre
por: Waglechner, Nicholas, et al.
Publicado: (2022)

2663. Impact of Pre-Transplant Microbiology on Acute Outcomes in Cystic Fibrosis Patients Receiving Bilateral Lung Transplants
por: (Michael) Ji, Xincheng, et al.
Publicado: (2019)

Impact of Cystic Fibrosis Transmembrane Conductance Regulator Therapy on Chronic Rhinosinusitis and Health Status: Deep Learning CT Analysis and Patient-reported Outcomes
por: Beswick, Daniel M., et al.
Publicado: (2022)

Objective and patient‐based measures of chronic rhinosinusitis in people with cystic fibrosis treated with highly effective modulator therapy
por: Beswick, Daniel M., et al.
Publicado: (2022)

Management Issues for Adolescents with Cystic Fibrosis
por: Withers, Adelaide Lindsay
Publicado: (2012)

Corticosteroid use and increased CXCR2 levels on leukocytes are associated with lumacaftor/ivacaftor discontinuation in cystic fibrosis patients homozygous for the F508del CFTR mutation
por: Pohl, Kerstin, et al.
Publicado: (2018)

Histo-Blood Group Gene Polymorphisms as Potential Genetic Modifiers of Infection and Cystic Fibrosis Lung Disease Severity
por: Taylor-Cousar, Jennifer L., et al.
Publicado: (2009)

Surgical Management of Chronic Rhinosinusitis in Cystic Fibrosis
por: Zheng, Zhong, et al.
Publicado: (2019)

Novel therapeutic approaches for the management of cystic fibrosis
por: Jaques, Ryan, et al.
Publicado: (2020)

Prevalence and Risk Factors for Low Bone Mineral Density in Adults With Cystic Fibrosis
por: Boyle, Rebecca L, et al.
Publicado: (2022)

Weight increase in people with cystic fibrosis on CFTR modulator therapy is mainly due to increase in fat mass
por: Mouzaki, Marialena, et al.
Publicado: (2023)

Update on the management of vitamins and minerals in cystic fibrosis
por: Sankararaman, Senthilkumar, et al.
Publicado: (2022)

Understanding Cystic Fibrosis Comorbidities and Their Impact on Nutritional Management
por: Patel, Dhiren, et al.
Publicado: (2022)

Management of refractory Pseudomonas aeruginosa infection in cystic fibrosis
por: Sordé, Roger, et al.
Publicado: (2011)

Physiotherapeutic management strategies for the treatment of cystic fibrosis in adults
por: Daniels, Tracey
Publicado: (2010)

Chronic Rhinosinusitis in Cystic Fibrosis: Diagnosis and Medical Management
por: Safi, Chetan, et al.
Publicado: (2019)

Infection prevention and chronic disease management in cystic fibrosis and noncystic fibrosis bronchiectasis
por: Lommatzsch, Sherstin T.
Publicado: (2020)

Role of vitamin D in cystic fibrosis and non-cystic fibrosis bronchiectasis
por: Moustaki, Maria, et al.
Publicado: (2017)

Cystic Fibrosis
por: Gibson, Lewis E.
Publicado: (1969)

Cystic Fibrosis
por: Dodge, J A
Publicado: (1997)

Pulmonary Bacterial Communities in Surgically Resected Noncystic Fibrosis Bronchiectasis Lungs Are Similar to Those in Cystic Fibrosis
por: Maughan, Heather, et al.
Publicado: (2012)

A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One F508del Allele
por: Zemanick, Edith T., et al.
Publicado: (2021)

Immunoreactive Trypsinogen in Infants Born to Women with Cystic Fibrosis Taking Elexacaftor–Tezacaftor–Ivacaftor
por: Patel, Payal, et al.
Publicado: (2023)

US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis
por: Floto, R Andres, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_unv03gt7l5g2f2r5norshi7fuj